Gemcitabine

Catalog No.S1714

Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Price Stock Quantity  
USD 130 In stock
USD 97 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Gemcitabine  Chemical Structure

Gemcitabine Chemical Structure
Molecular Weight: 263.2

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Gemcitabine is available in the following compound libraries:

Product Information

  • Compare DNA/RNA Synthesis Inhibitors
    Compare DNA/RNA Synthesis Products
  • Research Area

Product Description

Biological Activity

Description Gemcitabine is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MV-4-11M12zdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDDTWM2OD1yLkCwNFQ2QCCwTR?=MYDTRW5ITVJ?
ES4NGHKdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\sOoFwUUN3ME2wMlAxODZ3MzDuUS=>NXXRcnVZW0GQR1XS
ACHNM17tN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTBwMECwPFg4KG6PNU\C[nJOW0GQR1XS
KYSE-510NULQb5BWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPXPFVKSzVyPUCuNFAxQTd3IH7NM2HxOXNCVkeHUh?=
EW-7MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfMTWM2OD1yLkCwNlU5KG6PNH7Hb5ZUSU6JRWK=
BFTC-905NGDWOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\HTWM2OD1yLkCwOVE2KG6PNUHISml1W0GQR1XS
KE-37NYnGWnViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vve2lEPTB;MD6wNFU3OSCwTR?=M3voVnNCVkeHUh?=
SBC-5MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzhTWM2OD1yLkCwOVchdk1?NVvGUXRrW0GQR1XS
NKM-1NEf5dndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnaSZFKSzVyPUCuNFA4ODlibl2=M1PmSHNCVkeHUh?=
RH-1MlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfMS5BKSzVyPUCuNFA4OThibl2=MXPTRW5ITVJ?
ALL-POM4\PbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvzTWM2OD1yLkCwPFMhdk1?M{\HRnNCVkeHUh?=
QIMR-WILM1Tib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGO4cZhKSzVyPUCuNFA5QTRibl2=MmfLV2FPT0WU
A375NHG3bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTBwMEC5PVUhdk1?NG\GNZJUSU6JRWK=
SIG-M5MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTBwMEGwOEBvVQ>?M{K3eXNCVkeHUh?=
KGNNHvQNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWP4XmUzUUN3ME2wMlAyODhibl2=M2PFT3NCVkeHUh?=
EW-13MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fIW2lEPTB;MD6wNVEzKG6PM{jrPXNCVkeHUh?=
NCI-SNU-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLRW5FVUUN3ME2wMlAyPiCwTR?=MVPTRW5ITVJ?
PSN1NGfZWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4r3[mlEPTB;MD6wNVY2KG6PMoPRV2FPT0WU
HUTU-80NUnRcZRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{DBT2lEPTB;MD6wNVY3KG6PMYnTRW5ITVJ?
EW-16MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTBwMEKzJI5ONWrSS3o4W0GQR1XS
786-0NYTtT5NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\WPWlEPTB;MD6wNlMhdk1?MmnpV2FPT0WU
ES1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkD5TWM2OD1yLkCyOlghdk1?NWLuXGYxW0GQR1XS
RKOM2\IUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrLTWM2OD1yLkCyO|khdk1?MXfTRW5ITVJ?
ESS-1M1XONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTBwMEK4OkBvVQ>?MVXTRW5ITVJ?
SK-UT-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2eyUWlEPTB;MD6wNlk4KG6PM4\TWXNCVkeHUh?=
LB2241-RCCMlvyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DQ[GlEPTB;MD6wN|E5KG6PMlP1V2FPT0WU
CHL-1M2DNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33QWWlEPTB;MD6wN|I1KG6PM2\1RXNCVkeHUh?=
SW1783NGnqT5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTEPVBKSzVyPUCuNFM{PiCwTR?=MVnTRW5ITVJ?
MEL-JUSOM{nNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\sT2lEPTB;MD6wN|kyKG6PMoLtV2FPT0WU
HT-29M{X6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjQc4lKSzVyPUCuNFQyOyCwTR?=NGXWUFBUSU6JRWK=
SNG-MMmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LofGlEPTB;MD6wOFI2KG6PMVfTRW5ITVJ?
TE-15MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvsSm1KSzVyPUCuNFQ3PCCwTR?=MY\TRW5ITVJ?
HOSNUfZc2FQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrBSIJPUUN3ME2wMlA1QCCwTR?=NV\sNIloW0GQR1XS
BB65-RCCMl\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7v[VFKSzVyPUCuNFUyOiCwTR?=MlnHV2FPT0WU
HCE-4MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYS5OmFrUUN3ME2wMlA2Ojhibl2=NYXhcJJoW0GQR1XS
MHH-ES-1M1np[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPhTWM2OD1yLkC1N|Ehdk1?NHn4fpBUSU6JRWK=
RPMI-7951M1THVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjPOolKSzVyPUCuNFU1OSCwTR?=MV;TRW5ITVJ?
IST-SL2Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnLzTWM2OD1yLkC1PFQhdk1?NUW0eFdMW0GQR1XS
CMKM3ftemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Hz[2lEPTB;MD6wOVg3KG6PNYC5OJJrW0GQR1XS
GR-STMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTBwMEW5OUBvVQ>?NI\KRZhUSU6JRWK=
NALM-6MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPlSWxKSzVyPUCuNFYzOiCwTR?=MW\TRW5ITVJ?
RPMI-6666NVmwXYdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{S2XmlEPTB;MD6wOlUzKG6PM2rl[3NCVkeHUh?=
LC-2-adM4\heWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17jeWlEPTB;MD6wOlU{KG6PNIPESZJUSU6JRWK=
ARH-77MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTBwMEexNUBvVQ>?Mnr2V2FPT0WU
IST-MEL1NYTJ[Zl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHvVINKSzVyPUCuNFczPiCwTR?=M3P0UnNCVkeHUh?=
SW1710MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTBwMEe1NUBvVQ>?NFjkPIlUSU6JRWK=
DELMnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDmTWM2OD1yLkC4PFchdk1?NWTpVHdrW0GQR1XS
AGSMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\NVZRKSzVyPUCuNFkxOiCwTR?=MlrXV2FPT0WU
NCI-H2122MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzoTWM2OD1yLkC5OFYhdk1?MV7TRW5ITVJ?
HSC-4Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXLTWM2OD1yLkGwNkBvVQ>?NIDsNoZUSU6JRWK=
AM-38MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIP2ZlNKSzVyPUCuNVIyKG6PNYPTOWdzW0GQR1XS
769-PMmH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnWbJFKSzVyPUCuNVI{KG6PM2n6[HNCVkeHUh?=
RT-112M{e2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TYfmlEPTB;MD6xNlchdk1?NHH4[llUSU6JRWK=
MCF7M3Lrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v6cGlEPTB;MD6xN|Yhdk1?NHXUcnFUSU6JRWK=
IGROV-1NXn3VXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne4TWM2OD1yLkG0OUBvVQ>?NUL4UolDW0GQR1XS
OCI-AML2NFX3dmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LUeGlEPTB;MD6xOFchdk1?MkTRV2FPT0WU
NCI-H1299M4GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnlbYlKSzVyPUCuNVU4KG6PMXzTRW5ITVJ?
A431MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\LXGJrUUN3ME2wMlE5OyCwTR?=M{fuXXNCVkeHUh?=
SW982NWHOXmJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPWe3N5UUN3ME2wMlIyOyCwTR?=M2nKdXNCVkeHUh?=
BB30-HNCNHHVe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXWTWM2OD1yLkKzNUBvVQ>?NFvTZmdUSU6JRWK=
ACNMoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4CzZ2lEPTB;MD6yOFQhdk1?NVvNclJmW0GQR1XS
647-VMoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\RVmlEPTB;MD6yOFghdk1?MlvRV2FPT0WU
SK-PN-DWMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\l[FVKSzVyPUCuNlY3KG6PNH2zdW5USU6JRWK=
LCLC-97TM1NUTwSlBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jPdGlEPTB;MD6yOlchdk1?NVnue5JXW0GQR1XS
LB1047-RCCNH;ROpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXjXYFmUUN3ME2wMlI3QSCwTR?=NYrR[YdrW0GQR1XS
A2780NV3lSmpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nFb2lEPTB;MD6yO{BvVQ>?M2jWVHNCVkeHUh?=
C-33-ANFz2VmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYrJR|UxRTBwMkezJI5ONITQR5lUSU6JRWK=
NCI-H2228MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwM{G0JI5ONHz0cGhUSU6JRWK=
TE-5NYL1NZdqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVuzU|RrUUN3ME2wMlMyPiCwTR?=M4T4fXNCVkeHUh?=
HC-1NEjR[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwM{K3JI5ONEXDW|BUSU6JRWK=
SK-MES-1M3nJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnNcppnUUN3ME2wMlMzQCCwTR?=NV;0cGRvW0GQR1XS
NCI-H1355NVLWTppnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHlUXpFUUN3ME2wMlM5OSCwTR?=M1[zVXNCVkeHUh?=
YKG-1M{nkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3jVeGlEPTB;MD60NVkhdk1?NUnNXlNUW0GQR1XS
RS4-11MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33EPGlEPTB;MD60N|Mhdk1?NX\6eGVuW0GQR1XS
DaoyM2PucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTBwNEW2JI5OMV\TRW5ITVJ?
A3-KAWNVnNPGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXnJR|UxRTBwNUWxJI5ONEHrbG5USU6JRWK=
SK-MEL-30NXLiUY9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3nYbWlEPTB;MD61OVQhdk1?NHzle3hUSU6JRWK=
U031MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXj5PYNjUUN3ME2wMlU3PSCwTR?=NWnkSlZpW0GQR1XS
SK-LMS-1NVHnVXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4D3OWlEPTB;MD61O|ghdk1?NF3YRmZUSU6JRWK=
ES6MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljMTWM2OD1yLkW4OkBvVQ>?M{O5NXNCVkeHUh?=
EoL-1-cellMofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXTSHJKSzVyPUCuOlE3KG6PNGTz[nFUSU6JRWK=
NCI-H2009M1;4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1yy[WlEPTB;MD62NVkhdk1?NYHuUo9vW0GQR1XS
A4-FukMlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\jOYRKSzVyPUCuOlI3KG6PMXvTRW5ITVJ?
KYSE-270Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLJSnhKSzVyPUCuOlM1KG6PNHvxXFFUSU6JRWK=
SK-LU-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfUb3FKSzVyPUCuOlU2KG6PNEXkbmhUSU6JRWK=
SW872NFjwNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHNb3E4UUN3ME2wMlc3PSCwTR?=MUHTRW5ITVJ?
ES8MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fod2lEPTB;MD63PEBvVQ>?NHnnfpBUSU6JRWK=
G-402MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUfJR|UxRTBwN{i0JI5OM3vub3NCVkeHUh?=
ATN-1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XqWWlEPTB;MD64NFchdk1?NFn1XZlUSU6JRWK=
DoTc2-4510M3\JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnY[29KSzVyPUCuPVAyKG6PMVzTRW5ITVJ?
MES-SAM4rMcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTBwOUC1JI5ONELLWGdUSU6JRWK=
SF268MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTBwOUK3JI5ONHn5bFhUSU6JRWK=
SF539M3rYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2mxZ2lEPTB;MT6wNkBvVQ>?MXnTRW5ITVJ?
NB69MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTFwMEWgcm0>NGrmfo5USU6JRWK=
8505CMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HicmlEPTB;MT6wOkBvVQ>?MUDTRW5ITVJ?
CAL-12TNIjoWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPQNmFIUUN3ME2xMlA5KG6PMmLFV2FPT0WU
BHYMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDld3A{UUN3ME2xMlE1KG6PNYG0dIZrW0GQR1XS
LB647-SCLCM{HxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzETWM2OD1zLkG4JI5OMW\TRW5ITVJ?
CAL-62MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13SbGlEPTB;MT6yNkBvVQ>?MVTTRW5ITVJ?
MEG-01NX24OlRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vuV2lEPTB;MT6yO{BvVQ>?NF60Z5ZUSU6JRWK=
MG-63MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\3[mlEPTB;MT6zN{BvVQ>?MV7TRW5ITVJ?
SW620NHPaZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkD1TWM2OD1zLkO1JI5OMVTTRW5ITVJ?
A388NFXuVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTFwM{[gcm0>NYPsdVJ5W0GQR1XS
BCPAPMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DleWlEPTB;MT60OUBvVQ>?MmTuV2FPT0WU
P30-OHKMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlrrTWM2OD1zLkS2JI5OM4KwUHNCVkeHUh?=
Ca9-22NIH0[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVO1TYNVUUN3ME2xMlU1KG6PNEnoOJpUSU6JRWK=
VMRC-RCZNGKzSplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTFwNUSgcm0>NWXLe5FPW0GQR1XS
LOXIMVIM2r3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTFwNjDuUS=>NInzWmtUSU6JRWK=
L-540MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTFwNjDuUS=>NWnzOotFW0GQR1XS
NTERA-S-cl-D1NHi0WnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmn3TWM2OD1zLk[0JI5OMn;BV2FPT0WU
MFH-inoMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX:wNGJKUUN3ME2xMlY3KG6PMXvTRW5ITVJ?
Calu-6NGDoPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTFwN{Ogcm0>MkO0V2FPT0WU
HELNXvPO2dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTFwN{mgcm0>M{LlOHNCVkeHUh?=
CAL-33NWjSVlF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;6TWM2OD1zLki5JI5ONETFZXpUSU6JRWK=
HSC-3NFP5TmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4P1fWlEPTB;MT65NUBvVQ>?NW\CR|JEW0GQR1XS
KU812NUXwbWVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWj2b21XUUN3ME2xMlkyKG6PNHjWSXNUSU6JRWK=
EB2M4TSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLROWhyUUN3ME2yMlAyKG6PNYHYbIdrW0GQR1XS
SRMmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTJwMUKgcm0>MVLTRW5ITVJ?
NCI-H2087Mn;VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLNRmFiUUN3ME2yMlE1KG6PM4DyeHNCVkeHUh?=
H4MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrBTYVKSzVyPUKuNVghdk1?MoTmV2FPT0WU
EW-1MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWrtXlJ4UUN3ME2yMlIzKG6PNUe2c5FFW0GQR1XS
MC-IXCM3HMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF3hUpZKSzVyPUKuNlYhdk1?M3TQb3NCVkeHUh?=
NCI-H727NFzUN2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MULJR|UxRTJwNUGgcm0>MmXOV2FPT0WU
MRK-nu-1MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moe1TWM2OD1{LkW3JI5OMkH0V2FPT0WU
COLO-668NVqySmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2qwTmlEPTB;Mj62OkBvVQ>?MWTTRW5ITVJ?
CGTH-W-1MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TpNmlEPTB;Mj63NkBvVQ>?NIjsTWJUSU6JRWK=
CHP-212M3fFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRTJwN{Wgcm0>M2XUT3NCVkeHUh?=
GI-1MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33xfGlEPTB;Mj63OkBvVQ>?MnLhV2FPT0WU
HCC1806MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mnu3TWM2OD1{LkmxJI5OM4K3[3NCVkeHUh?=
HLENGnXO3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\IdI9KSzVyPUOgcm0>NFXJU49USU6JRWK=
HSC-2MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTNwMEOgcm0>NVzxeGtJW0GQR1XS
DMS-273MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TyZWlEPTB;Mz6wO{BvVQ>?NV7RUVNtW0GQR1XS
DU-4475MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2[3N2lEPTB;Mz6xOEBvVQ>?M2nwXnNCVkeHUh?=
LXF-289MnPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfrTWM2OD1|LkOxJI5OM1\tfXNCVkeHUh?=
PANC-03-27Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\sdGd{UUN3ME2zMlUyKG6PM1HJcXNCVkeHUh?=
GAMGNU\VZ4Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo[1TWM2OD1|Lke0JI5OMlj4V2FPT0WU
NCI-H522NVXicI5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\EVnlzUUN3ME20MlM1KG6PNYLRdVJMW0GQR1XS
SW626NGLncVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1i1R2lEPTB;ND60OkBvVQ>?M4q3[HNCVkeHUh?=
HT-144MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYHJR|UxRTRwOUKgcm0>NGPjOIVUSU6JRWK=
MEL-HOM4nKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIjI[ZRKSzVyPUWuNVYhdk1?MYfTRW5ITVJ?
BE-13MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPKTWM2OD13LkKxJI5OMXLTRW5ITVJ?
VA-ES-BJNGPlXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTVwMk[gcm0>MVPTRW5ITVJ?
NCI-H441MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\6d21KSzVyPUWuOkBvVQ>?NGi1NXZUSU6JRWK=
KP-4MnfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jOTWlEPTB;NT62NUBvVQ>?NF33NYJUSU6JRWK=
LoVoNEmxWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LMSGlEPTB;NT63NUBvVQ>?M2HpW3NCVkeHUh?=
HT-1080NHrPdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TPemlEPTB;NT64N{BvVQ>?MmnaV2FPT0WU
GB-1MnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTVwOESgcm0>NWLkfHBKW0GQR1XS
IA-LMNGju[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mny0TWM2OD13LkmxJI5OM4PNfHNCVkeHUh?=
8-MG-BAMkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2TNT2lEPTB;NT65N{BvVQ>?M2HSeHNCVkeHUh?=
SK-HEP-1NVjSepVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUfJR|UxRTZwMUSgcm0>Ml3nV2FPT0WU
697M3ftcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV\oN4J[UUN3ME22MlI2KG6PMnnoV2FPT0WU
KYSE-450Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTZwM{Kgcm0>M{H1dnNCVkeHUh?=
HCC2998NFXJSXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTZwM{Sgcm0>M{nKOXNCVkeHUh?=
HD-MY-ZNEfuT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDn[Xl4UUN3ME22MlY5KG6PNIPRVY1USU6JRWK=
OS-RC-2NYXlemlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;uXGJKSzVyPU[uOlghdk1?NYewemdMW0GQR1XS
SF126NFq1dVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYDPVGJFUUN3ME23MlA2KG6PM1jaOnNCVkeHUh?=
Ca-SkiM1vuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\KO2pjUUN3ME23MlA6KG6PNFHWS3pUSU6JRWK=
NCI-H358NFPEbWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRTdwMU[gcm0>NXfLepVMW0GQR1XS
J82NFzQfIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTaeYpuUUN3ME23MlQyKG6PNIPxTXFUSU6JRWK=
NCI-H2342Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPkTWM2OD15Lk[zJI5OM1\M[3NCVkeHUh?=
OVCAR-8MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTdwOTDuUS=>M364cXNCVkeHUh?=
TE-8MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoOwTWM2OD16IH7NM4m5O3NCVkeHUh?=
ETK-1NWO5PWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\iN2lEPTB;OD6wPEBvVQ>?MVvTRW5ITVJ?
HAL-01MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlexTWM2OD16LkKgcm0>NGjqTm9USU6JRWK=
KYSE-150M1rlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLnenREUUN3ME24MlQ4KG6PMln6V2FPT0WU
NCI-H810M4\hW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRThwNU[gcm0>M4fVc3NCVkeHUh?=
ONS-76M1;PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjqdmlwUUN3ME24MlY5KG6PMmHOV2FPT0WU
NMC-G1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmrqTWM2OD16Lke2JI5OMlzsV2FPT0WU
C3AMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjBc|ZKSzVyPUiuPFQhdk1?MkS4V2FPT0WU
PA-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2jGWmlEPTB;OD65PUBvVQ>?MX3TRW5ITVJ?
SH-4M33OTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTlwMEKgcm0>NUHHSJp7W0GQR1XS
EFO-27MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3mU4NRUUN3ME25MlA2KG6PMY\TRW5ITVJ?
CAPAN-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRTlwMkOgcm0>M13iVnNCVkeHUh?=
DU-145M3L1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTlwMkmgcm0>MlPvV2FPT0WU
A101DMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rkdWlEPTB;OT6zO{BvVQ>?MXfTRW5ITVJ?
ST486MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\iVWlEPTB;OT60NUBvVQ>?MYnTRW5ITVJ?
NCI-H1437NY\GTG0xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrHd2JoUUN3ME25MlQzKG6PNWPWe3lmW0GQR1XS
HGC-27NHnuR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jycGlEPTB;OT62JI5OMnLJV2FPT0WU
8305CNV\yR|JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4joR2lEPTB;OT62OEBvVQ>?MmTZV2FPT0WU
OCUB-MNFPYWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4roZmlEPTB;MUCuNFMhdk1?MVPTRW5ITVJ?
COLO-679MnnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTFyLkC3JI5OMVnTRW5ITVJ?
Detroit562NXzKepdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEe5ZZpKSzVyPUGwMlQzKG6PM1O1RXNCVkeHUh?=
A204NW\tdmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTOUnBOUUN3ME2xNU4yPiCwTR?=MnW1V2FPT0WU
NCI-H1734MoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk[0TWM2OD1zMT6yPUBvVQ>?NX;6T41WW0GQR1XS
MC-CARMmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI\YeWpKSzVyPUGxMlU5KG6PMXzTRW5ITVJ?
NCI-H2170NXLVeGlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4joS2lEPTB;MUGuPVchdk1?MWXTRW5ITVJ?
NCI-SNU-5MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NISyWo9KSzVyPUGyMlE{KG6PNFTJdmRUSU6JRWK=
HCE-TM2fa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfrSlhKSzVyPUGyMlQzKG6PMVfTRW5ITVJ?
KYSE-180M4jtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIK2[3ZKSzVyPUGyMlgyKG6PM3jLZ3NCVkeHUh?=
C8166NUjJPIlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrUVoNKSzVyPUGzMlA5KG6PM2PWfHNCVkeHUh?=
NCI-H460MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1GySmlEPTB;MUOuOVQhdk1?M2\kVnNCVkeHUh?=
SNU-449NF\sOnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTF|Lke3JI5ONVfjVllvW0GQR1XS
MDA-MB-468NHXzRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{L0cmlEPTB;MUSuNVIhdk1?MXXTRW5ITVJ?
COR-L23MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUHUWpA5UUN3ME2xOE4yOyCwTR?=MVLTRW5ITVJ?
CTV-1NEP2R2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnjPTWM2OD1zND6xOEBvVQ>?MXPTRW5ITVJ?
BL-41NWrrfVBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIP5bGhKSzVyPUG0MlM4KG6PNFi4eWtUSU6JRWK=
IGR-1NXXOUo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjrNG84UUN3ME2xOE41OiCwTR?=NUTodW9yW0GQR1XS
TK10M2L6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGK4SotKSzVyPUG0MlQ6KG6PNHu5cZdUSU6JRWK=
REHNF\DbWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTF2LkWxJI5OMkXXV2FPT0WU
LU-139M{Pnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;NR5BLUUN3ME2xOE42QSCwTR?=NWfoXlJ5W0GQR1XS
KP-N-YSNXnZUIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfENY5LUUN3ME2xOE46PyCwTR?=MUPTRW5ITVJ?
PANC-10-05NFW3PZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2KxO2lEPTB;MUWuN|ghdk1?NVzv[oR{W0GQR1XS
HL-60NETscZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTF3Lk[5JI5OMo\xV2FPT0WU
T84NEe1dXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DiTWlEPTB;MUWuPVYhdk1?MlflV2FPT0WU
RPMI-8226MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rMZmlEPTB;MU[uNFIhdk1?MnHuV2FPT0WU
UM-UC-3MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWq3cVlrUUN3ME2xOk4yPiCwTR?=MnLBV2FPT0WU
TE-10MmH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTF4LkKxJI5ONGnpToxUSU6JRWK=
CAL-148M1vJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjQWIZKSzVyPUG3MlI{KG6PNXvIe3RHW0GQR1XS
BV-173MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2T4eWlEPTB;MUeuNlchdk1?MYPTRW5ITVJ?
Calu-3MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWfkW2tJUUN3ME2xO{4zQSCwTR?=NHvtb5hUSU6JRWK=
RPMI-2650MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLqdnZWUUN3ME2xO{42QSCwTR?=MnLLV2FPT0WU
MKN45M3vFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3GzeWlEPTB;MUeuO|Mhdk1?MXPTRW5ITVJ?
NUGC-3NXnxUGhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;QSmNKSzVyPUG4MlM1KG6PMkHZV2FPT0WU
NCI-H520MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHu4N|JKSzVyPUG4Mlc4KG6PM1y0dHNCVkeHUh?=
CCRF-CEMM3O3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfaSWp[UUN3ME2xPE45PSCwTR?=NYXtNnlDW0GQR1XS
NCI-H2405MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37xd2lEPTB;MUmuNUBvVQ>?NVjtd2REW0GQR1XS
ES7MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHyNXRuUUN3ME2xPU44PiCwTR?=NGjiRlFUSU6JRWK=
BPH-1NIH1NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPpSFd5UUN3ME2yNE4zQCCwTR?=MXXTRW5ITVJ?
SASMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1q4XWlEPTB;MkCuOUBvVQ>?Ml:3V2FPT0WU
HuCCT1MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIi4cldKSzVyPUKwMlU5KG6PMnmyV2FPT0WU
LOUCYMlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnhe|dKSzVyPUKwMlY3KG6PMVHTRW5ITVJ?
NCI-H292NXLlWFNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\jTWM2OD1{MD63PUBvVQ>?Mmm0V2FPT0WU
G-361NGCwRmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjrVm1KSzVyPUKxMlA4KG6PM{TiN3NCVkeHUh?=
M059JM1nn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrITWM2OD1{MT6wPEBvVQ>?M1LhfHNCVkeHUh?=
NCI-H1651NEKyXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELRN2lKSzVyPUKxMlEyKG6PNYjEeWdyW0GQR1XS
KALS-1M4DkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXCfXI4UUN3ME2yNU4{QSCwTR?=NELYXHBUSU6JRWK=
DJM-1NUO5dlhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HHWmlEPTB;MkGuOVkhdk1?MkPwV2FPT0WU
AU565MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXlVYlKSzVyPUKxMlg{KG6PM3TLUXNCVkeHUh?=
HCC38Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIK1Z|FKSzVyPUKxMlk2KG6PNGjOW5NUSU6JRWK=
U251NULleoMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnFXnlKSzVyPUKyMlI4KG6PNInkZnpUSU6JRWK=
ABC-1NXnLWXA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTJ{Lk[1JI5OM3HqSnNCVkeHUh?=
SK-NEP-1MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjKPGpKSzVyPUKyMlk{KG6PNXvGXZRJW0GQR1XS
CESSNHPDbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XJdmlEPTB;MkOuNVkhdk1?NGjOXHlUSU6JRWK=
MIA-PaCa-2NGTEO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\SPGlEPTB;MkOuN|Yhdk1?MULTRW5ITVJ?
SUP-T1M17mOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{\IS2lEPTB;MkOuOFchdk1?NU\tNZFXW0GQR1XS
L-428MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrFTWM2OD1{Mz62NkBvVQ>?NGrvNZZUSU6JRWK=
SW954NIKzOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fxUmlEPTB;MkOuOlghdk1?NHTzXnZUSU6JRWK=
HO-1-N-1M{fC[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnOzTWM2OD1{Mz63O{BvVQ>?NWDrNFFPW0GQR1XS
CHP-126MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LDfmlEPTB;MkSuNVQhdk1?M{L0b3NCVkeHUh?=
HMV-IINVHMPHczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;vPHRKSzVyPUK0MlM1KG6PMYXTRW5ITVJ?
NB10Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEXufFRKSzVyPUK0MlM4KG6PNIfqVZVUSU6JRWK=
A172NWO4Xol5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFPPfndKSzVyPUK0MlcyKG6PNEjE[|RUSU6JRWK=
MONO-MAC-6M3vEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkexTWM2OD1{ND64OEBvVQ>?NWXKdHVQW0GQR1XS
NCI-H1650NIG4enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LURWlEPTB;MkWuOEBvVQ>?Mk\uV2FPT0WU
NH-12Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXfMTmg6UUN3ME2yOU42KG6PMXLTRW5ITVJ?
ML-2MlHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXS3NmtsUUN3ME2yOU44PCCwTR?=NVq4PY1uW0GQR1XS
MZ2-MELMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFOxWpNKSzVyPUK2MlIzKG6PM2rITXNCVkeHUh?=
COLO-684NIHXUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDQTWM2OD1{Nj60NUBvVQ>?Ml:1V2FPT0WU
HuP-T4NX\JdXdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHs[pY2UUN3ME2yO{4{KG6PMkf6V2FPT0WU
SW837M36yWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXaTmFKSzVyPUK3MlYzKG6PMmXrV2FPT0WU
MDA-MB-231NX\kUFhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jLU2lEPTB;MkeuO|ghdk1?MXLTRW5ITVJ?
KYSE-140M37LZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH;CT2ZKSzVyPUK3MlkyKG6PMUfTRW5ITVJ?
NOMO-1MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTJ6Lk[4JI5OMoD1V2FPT0WU
GP5dM{fnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XRTGlEPTB;MkiuO|Ihdk1?NGXFe4dUSU6JRWK=
COR-L105MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTJ7LkSyJI5ONVjYUJZUW0GQR1XS
LS-411NNVvF[pBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vJU2lEPTB;MkmuPFghdk1?NH7YWVNUSU6JRWK=
NYMmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETLVHJKSzVyPUOwMlE5KG6PNVf6VFh5W0GQR1XS
NCI-H2030Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPFbotKSzVyPUOwMlQ2KG6PM{PDXXNCVkeHUh?=
CCF-STTG1NYTzUVJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zjOGlEPTB;M{GuOFIhdk1?M{HId3NCVkeHUh?=
NCI-H1703MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4fNNGlEPTB;M{GuO|ghdk1?Ml7YV2FPT0WU
TURNWDoNZhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2r5fGlEPTB;M{KuNFMhdk1?MU\TRW5ITVJ?
NOS-1NIHJ[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXr0dGNtUUN3ME2zNk41PCCwTR?=NVr5XWFJW0GQR1XS
A2058NIPEPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;JTmlEPTB;M{KuPFMhdk1?M{Tm[nNCVkeHUh?=
LCLC-103HNG\jR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnm5TWM2OD1|Mz6yOUBvVQ>?MXXTRW5ITVJ?
NCI-H510AMnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlv2TWM2OD1|Mz6yO{BvVQ>?MmDLV2FPT0WU
BC-1MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3PV3RKSzVyPUOzMlc4KG6PM{XHOHNCVkeHUh?=
SK-CO-1NV;s[WJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTN2LkCxJI5OMkPYV2FPT0WU
A673NVnzSFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHiTWM2OD1|ND6xO{BvVQ>?MkS4V2FPT0WU
VM-CUB-1M2PEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlrBTWM2OD1|ND62PUBvVQ>?NELjWW9USU6JRWK=
HHNInoN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoT0TWM2OD1|NT6wOkBvVQ>?MojoV2FPT0WU
CAL-27MoLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjZepNpUUN3ME2zOU4yPiCwTR?=NGr4PWtUSU6JRWK=
NEC8NWr3SGRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfPNYh5UUN3ME2zOU4{PyCwTR?=MUjTRW5ITVJ?
BxPC-3NFPqdGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTN4LkmxJI5ONIrRS5BUSU6JRWK=
SNB75MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrP[5JnUUN3ME2zO{4zPCCwTR?=NEjITYJUSU6JRWK=
NB13MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTN6LkKzJI5OM1jxRnNCVkeHUh?=
SK-OV-3M4K5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLv[WN6UUN3ME2zPE44PCCwTR?=NXnpfohtW0GQR1XS
ME-180M4O3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTN6Lkigcm0>NXnmWVh3W0GQR1XS
JiyoyeP-2003M2rHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfWNY1TUUN3ME2zPU4{QCCwTR?=NH35R3lUSU6JRWK=
LU-134-ANVW2[21QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDUZ3hKSzVyPUSwMlAzKG6PNWq4PXpCW0GQR1XS
LS-123NUXzOnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXMTWM2OD12MD6yPEBvVQ>?NXHVbVA3W0GQR1XS
COLO-800NVXaR|hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzPNopKSzVyPUSwMlU3KG6PM1LLVnNCVkeHUh?=
LB831-BLCNWizTXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHITWM2OD12MT64OUBvVQ>?M4q2WXNCVkeHUh?=
NCI-H747MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkCwTWM2OD12Mj6yPEBvVQ>?MnzMV2FPT0WU
MZ7-melMlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoToTWM2OD12Mj62OkBvVQ>?MYrTRW5ITVJ?
GT3TKBMnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HNbWlEPTB;NEKuO|Ihdk1?NF;JPWRUSU6JRWK=
MOLT-16NFTDb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnu0TWM2OD12Mz6wOUBvVQ>?M1;RR3NCVkeHUh?=
23132-87NF\r[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFHEc49KSzVyPUSzMlA2KG6PM1r6WnNCVkeHUh?=
PF-382MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTR2LkKyJI5OMVXTRW5ITVJ?
ES3NWrkVppFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTR2Lk[gcm0>NIT2OYhUSU6JRWK=
SW756NIHaSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\zTWM2OD12NT6xOEBvVQ>?NVvSV5p7W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]
Features

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hertel LW, et al. Cancer Res, 1990, 50(14), 4417-4422.

[2] Bruns CJ, et al. Clin Cancer Res, 2000, 6(5), 1936-1948.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02538432 Not yet recruiting Prostate Cancer|Non-Small Cell Lung Cancer|Breast Cancer University of Maryland January 2017 Phase 2
NCT02767557 Not yet recruiting Unresectable Pancreatic Carcinoma Herlev Hospital|Celgene|Roche Pharma AG October 2016 Phase 2
NCT02806687 Not yet recruiting Pancreatic Adenocarcinoma University Hospital, Toulouse|BIOTHERAPY department of th  ...more University Hospital, Toulouse|BIOTHERAPY department of the clinical center of investigation- CIC 1436, Toulouse|InvivoGen Therapeutics October 2016 Phase 2
NCT02741388 Not yet recruiting B-cell Lymphoma The Lymphoma Academic Research Organisation|Karyopharm Th  ...more The Lymphoma Academic Research Organisation|Karyopharm Therapeutics, Inc September 2016 Phase 1
NCT02723838 Not yet recruiting Muscle-invasive Transitional Cell Carcinoma of the Bladder Oncolytics Biotech September 2016 Phase 1

view more

Chemical Information

Download Gemcitabine SDF
Molecular Weight (MW) 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms LY-188011, NSC 613327
Solubility (25°C) * In vitro Water 16 mg/mL warming (60.79 mM)
DMSO 15 mg/mL (56.99 mM)
Ethanol <1 mg/mL
In vivo water 16mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 2'-​deoxy-​2',​2'-​difluoro-cytidine

Frequently Asked Questions

  • Question 1
    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

    Answer: Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related DNA/RNA Synthesis Products

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Blasticidin S HCl

    Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.

  • YK-4-279

    YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).

  • Cisplatin

    Cisplatin is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells.

    Features:One of the most widely used and most potent chemotherapeutic agents.

  • Gemcitabine HCl

    Gemcitabine HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

    Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.

  • Oxaliplatin

    Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

  • Bleomycin Sulfate

    Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

  • Fluorouracil (5-Fluoracil, 5-FU)

    Fluorouracil (5-Fluoracil, 5-FU) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells.

  • Carboplatin

    Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

    Features:A DNA synthesis inhibitor.

  • Cytarabine

    Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

    Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Recently Viewed Items

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us